DILTIAZEM HYDROCHLORIDE

Post-LOE

diltiazem hydrochloride

Accord Biopharma

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Apr 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DILTIAZEM HYDROCHLORIDE (diltiazem hydrochloride) by Accord Biopharma is clinical pharmacology the therapeutic benefits of diltiazem hydrochloride are believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscles. Approved for hypertension, chronic stable angina. First approved in 2020.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The therapeutic benefits of diltiazem hydrochloride are believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscles. Mechanism of Action: Hypertension: Diltiazem hydrochloride produces its…

Worked on DILTIAZEM HYDROCHLORIDE at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DILTIAZEM HYDROCHLORIDE

Mechanism of Action

Indications (2)